Cargando…

Metabolomics in High Grade Gliomas

Gliomas are central nervous system (CNS) cancers that are challenging to treat due to their high proliferation and mutation rates. High grade gliomas include grade 3 and grade 4 tumors, which characteristically have a poor prognosis despite advancements in diagnostic methods and therapeutic options....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Nina, Aboud, Orwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839194/
https://www.ncbi.nlm.nih.gov/pubmed/36643416
http://dx.doi.org/10.51520/2766-2586-17
_version_ 1784869434620379136
author Yu, Nina
Aboud, Orwa
author_facet Yu, Nina
Aboud, Orwa
author_sort Yu, Nina
collection PubMed
description Gliomas are central nervous system (CNS) cancers that are challenging to treat due to their high proliferation and mutation rates. High grade gliomas include grade 3 and grade 4 tumors, which characteristically have a poor prognosis despite advancements in diagnostic methods and therapeutic options. Advances in metabolomics are resulting in more insight as to how cancer modifies the metabolism of the cell and surrounding tissue. Hence, this avenue of research may also emerge as a way to precisely target metabolites unique to gliomas. These biomarkers may provide opportunities for glioma diagnosis, prognosis and future therapeutic intervention. In this review, we harvest the literature that highlights notable biomolecules in high grade gliomas and promising therapeutic targets and interventions.
format Online
Article
Text
id pubmed-9839194
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-98391942023-01-13 Metabolomics in High Grade Gliomas Yu, Nina Aboud, Orwa RAS Oncol Ther Article Gliomas are central nervous system (CNS) cancers that are challenging to treat due to their high proliferation and mutation rates. High grade gliomas include grade 3 and grade 4 tumors, which characteristically have a poor prognosis despite advancements in diagnostic methods and therapeutic options. Advances in metabolomics are resulting in more insight as to how cancer modifies the metabolism of the cell and surrounding tissue. Hence, this avenue of research may also emerge as a way to precisely target metabolites unique to gliomas. These biomarkers may provide opportunities for glioma diagnosis, prognosis and future therapeutic intervention. In this review, we harvest the literature that highlights notable biomolecules in high grade gliomas and promising therapeutic targets and interventions. 2022 2022-09-30 /pmc/articles/PMC9839194/ /pubmed/36643416 http://dx.doi.org/10.51520/2766-2586-17 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Yu, Nina
Aboud, Orwa
Metabolomics in High Grade Gliomas
title Metabolomics in High Grade Gliomas
title_full Metabolomics in High Grade Gliomas
title_fullStr Metabolomics in High Grade Gliomas
title_full_unstemmed Metabolomics in High Grade Gliomas
title_short Metabolomics in High Grade Gliomas
title_sort metabolomics in high grade gliomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839194/
https://www.ncbi.nlm.nih.gov/pubmed/36643416
http://dx.doi.org/10.51520/2766-2586-17
work_keys_str_mv AT yunina metabolomicsinhighgradegliomas
AT aboudorwa metabolomicsinhighgradegliomas